PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects. Our study focuses on the PPARγ ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes. We demonstrate, for the first time to our knowledge, that PPARγ is highly expressed...

全面介紹

書目詳細資料

發表在:	J Clin Invest
Principais autores:	Panigrahy, Dipak, Singer, Samuel, Shen, Lucy Q., Butterfield, Catherine E., Freedman, Deborah A., Chen, Emy J., Moses, Marsha A., Kilroy, Susan, Duensing, Stefan, Fletcher, Christopher, Fletcher, Jonathan A., Hlatky, Lynn, Hahnfeldt, Philip, Folkman, Judah, Kaipainen, Arja
格式:	Artigo
語言:	Inglês
出版:	American Society for Clinical Investigation 2002
主題:	Article
在線閱讀:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC151148/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12370270/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI15634
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!